ArticleFrontiers in allergy2026
Clinical observation of stapokibart in patients under 18 years of age with seasonal allergic rhinitis: a case series study of 20 cases.
Article in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The objective of this work was to investigate the efficacy and safety of stapokibart, an anti-IL-4R Methods: A retrospective analysis was conducted on 20 children with severe SAR who received stapokibart treatment during spring (March-April) and autumn (August-October) of 2025. The regimen consisted of an initial dose of 600 mg (two subcutaneous injections), followed by a maintenance dose of 300 mg (one injection) after 2 weeks, after which the treatment was discontinued. Children with comorbid atopic dermatitis (AD) ( Results: All 20 pediatric patients demonstrated significant reductions in nasal VAS scores compared with baseline after 1 month of treatment ( Conclusion: In this small case series, stapokibart rapidly and effectively alleviated nasal symptoms of SAR in children and adolescents, and may provide long-term symptom control across allergy seasons for patients with comorbid AD. The treatment demonstrated a good safety profile, offering novel insights into targeted therapy of comorbid allergic diseases in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.